TEVA Stock Analysis: Buy, Sell, or Hold?
TEVA - Teva Pharmaceutical Industries Limited American Depositary Shares
$31.75
-1.16 (-3.52%)
▼
5d:
-5.98%
30d:
-12.41%
90d:
+18.12%
HOLD
LOW Confidence
Analysis Updated: Mar 5, 2026 12:00 AM ET
Earnings: May 13, 2026
Get Alerted When TEVA Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
1 traders called TEVA this week
100% bullish • 0 bearish
100% bullish • 0 bearish
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: TEVA shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
📊 HOLD: TEVA shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$55.73
Based on 9.8% avg growth
INTRINSIC VALUE TODAY
$34.61
8.3% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 11.3x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: TEVA is currently trading at $31.75, which is considered oversold relative to its 30-day fair value range of $32.88 to $34.89. The stock's valuation (Forward PE: 10.6) is in line with its historical norms (11.3). Remarkably, the market is currently pricing in an annual earnings decline of 2.0% over the next few years. This pessimistic expectation contrasts with the company's recent 40.0% earnings growth, suggesting potential undervaluation if the company simply maintains stability.
Technical Outlook: Technically, TEVA is in a strong uptrend. The price is currently testing key support at $31.40. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 3.5% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $38.14 (+15.9%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, TEVA is in a strong uptrend. The price is currently testing key support at $31.40. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 3.5% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $38.14 (+15.9%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
OVERSOLD
Fair Price Range
$32.88 -
$34.89
Company Quality Score
58/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
72.4%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-3.5%)
- BULLISH: Trading below Wall St target ($38.14)
- CAUTION: Recommendation downgraded due to -6.0% 5-day decline
Fair Price Analysis
30-Day Fair Range
$32.88 -
$34.89
Current vs Fair Value
OVERSOLD
Support & Resistance Levels
Support Level
$31.40
Resistance Level
$35.18
Current Trend
Strong Uptrend
Technical data as of
Mar 5, 2026
Fundamental Context
Forward P/E (Next Year Est.)
10.61
Wall Street Target
$38.14
(+15.9%)
Revenue Growth (YoY)
11.4%
Earnings Growth (YoY)
40.0%
Profit Margin
8.2%
Valuation Discount vs History
-2.0% cheaper
PE vs Historical
10.6 vs 11.3
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-2.0%
(market-implied from PE analysis)
1-Year Target
$32.25
(-2%)
2-Year Target
$31.61
(-4%)
3-Year Target
$30.97
(-6%)
3-Yr Target (if PE normalizes)
(PE: 11→11)
$32.98
(+0%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 22.6, Growth: 15.6%)
$108.23
(+229%)
Base:
(SPY PE: 10.6, Growth: 15.6%)
$50.85
(+55%)
Bear:
(PE: 9.0, Growth: 15.6%)
$43.22
(+31%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (28x PE), but valuation improves significantly next year (11x PE) as earnings recover.
Trailing PE: 27.91 | Current EPS (TTM): $1.21
Bull Case
$74.29
(+119%)
Analyst growth 100.0%, PE expands to 30.7
Base Case
$67.54
(+100%)
Market implied 100.0%, PE stable at 27.9
Bear Case
$22.96
(-32%)
Severe decline -20.0%, PE contracts to 23.7
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 10.6 to 11.3
Stabilization Target:
$35.04
(+6.5%)
PE Expansion Potential:
+6.5%
Share & Embed Analysis
Last updated: March 06, 2026 5:14 AM ET
Data refreshes hourly during market hours. Next update: 6:14 AM
Data refreshes hourly during market hours. Next update: 6:14 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is TEVA showing a specific setup today?
Insider Activity (6 Months)
0
Buys
5
Sells
Net
INSIDERS SELLING
Recent Transactions
Amir Weiss
SELL
12300 shares
2025-12-16
Roberto Mignone
SELL
77400 shares
2025-12-16
Mark Sabag
SELL
216892 shares
2025-12-09
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences I… |
STRONG BUY
25 analysts |
$177 | 59 HOLD |
|
ZTS
Zoetis Inc |
STRONG BUY
19 analysts |
$154 | 58 HOLD |
|
LNTH
Lantheus Holdings Inc |
STRONG BUY
13 analysts |
$85 | 67 BUY |
|
BCRX
BioCryst Pharmaceuticals… |
STRONG BUY
12 analysts |
$21 | 56 HOLD |
|
AVDL
Avadel Pharmaceuticals P… |
STRONG BUY
8 analysts |
$21 | 62 BUY |
